Tempo Bioscience

Developing 10,000 human disease models

Tempo Bioscience

Developing 10,000 human disease models

Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our in-house developed proprietary technologies and cell-based products serve as valuable tools for the Biotechnology and Pharmaceutical industry.

Tempo creates human disease models for:

Human disease models

Spheroid and organoid models

Physiological barrier models

Therapeutic discovery assays

2-D and 3-D cell models

Cytotoxicity and toxicology applications

Lead optimization studies

Multi-cell type models

Gene therapy dosing models

Blood brain barrier models

Tempo’s Library of 22+ iPSC derivative cell types

  • Pericytes
  • Microglia
  • Osteoblasts
  • Melanocytes
  • Keratinocytes
  • Schwann cells
  • Motor Neurons
  • Sensory neurons
  • Cortical neurons
  • Neural progenitors
  • CD14+ Monocytes
  • Hepatic Stellate Cells
  • Dopaminergic neurons
  • Mesenchymal stem cells
  • Phagocytes (Macrophage)
  • Endodermal Progenitor Cells
  • Astrocytes (type I and type II)
  • Hepatocytes (albumin positive)
  • Retinal Pigment Epithelial (RPEs)
  • Oligodendrocyte Progenitor Cells
  • Kidney Proximal Tubule Cells & Podocytes
  • Brain Microvascular Endothelial Cells (BMECs)
  • Cardiomyocytes (atrial and ventricular; mixture)

Leadership Team

Angela L. Huang PhD

Founder and President

Angela founded Tempo Bioscience, Inc in 2013. She developed, patented, and commercialized Tempo’s core technologies. Together with Tempo’s team, the enabling technologies became available to scientists worldwide. Angela is listed as an inventor on numerous patents -issued and pending- worldwide and has published in journals such as Nature. She received her scientific training from UC Berkeley, UC San Diego, and UC San Francisco.

Robert “Bob” M. Kay PhD

Chief Advisor

Bob is a biotech-pharmaceutical industry veteran, with 25+ years of experience as a research scientist, corporate vice president of research (GenPharm International), and, most recently, former CEO of Origen Therapeutics Inc for 12 years. He is also the Managing Member of Parallax Biotechnology Advisors LLC. Bob is a member of the Tempo Bioscience advisory board.


Christopher Aguilar JD

Corporate General Counsel

Chris has 25+ years of legal experience as a trial lawyer and in-house general counsel. He has worked with a wide range of companies in their legal and business matters. Formerly, Chris was the general counsel of Merriman Curhan Ford & Co.

Eric P. Mirabel JD LLM

Intellectual Property Attorney

Eric is a well-known IP attorney and author, specializing in high-tech patents including biotechnology, chemistry, electronics, and business methods involving softwares. His legal articles are cited by lawyers and by the courts, including the US Federal Circuit Court of Appeals. Formerly, Eric was the Head of IP for Tanox Inc and BioArray Solutions Ltd.